Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.…
Wall Street Analysts Predict an 119.28% Upside in Alpha Cognition Inc. (ACOG): Here's What You Should Know
Alpha Cognition (NASDAQ: ACOG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 71 employees.
The shares were at 9.000 USD on 20 November 2026, up 52.0% over 52 weeks. Its 52-week range is 4.500 USD to 10.14 USD: the price is 11.2% below the high and 100.0% above the low.
Its market capitalisation is 198.37M USD.
Alpha Cognition reports return on equity of -33.1%, an operating margin of -141.6% and revenue up 173.8% year over year.
It holds more cash than debt, a net cash position of 37.80M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 18.20 USD is 102.2% above the current price. The next earnings report is expected on 25 March 2027.